196 related articles for article (PubMed ID: 38071029)
21. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
22. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
[TBL] [Abstract][Full Text] [Related]
23. Discrepancies between positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography in a cohort of oncological patients.
Oh G; O'Mahoney E; Jeavons S; Law P; Ngai S; McGill G; Yu C; Miles KA
J Med Imaging Radiat Oncol; 2020 Apr; 64(2):204-210. PubMed ID: 32037655
[TBL] [Abstract][Full Text] [Related]
24. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Ferraro DA; Burger IA
Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
[TBL] [Abstract][Full Text] [Related]
25. Aortic valve stenosis-multimodality assessment with PET/CT and PET/MRI.
Tzolos E; Andrews JP; Dweck MR
Br J Radiol; 2020 Sep; 93(1113):20190688. PubMed ID: 31647323
[TBL] [Abstract][Full Text] [Related]
26. Fluorodeoxyglucose-PET/Computed Tomography-Guided Biopsy.
Cerci JJ; Tabacchi E; Bogoni M
PET Clin; 2016 Jan; 11(1):57-64. PubMed ID: 26590444
[TBL] [Abstract][Full Text] [Related]
27. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO
Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476
[TBL] [Abstract][Full Text] [Related]
28. Current Update on PET/MRI in Gynecological Malignancies-A Review of the Literature.
Virarkar M; Vulasala SS; Calimano-Ramirez L; Singh A; Lall C; Bhosale P
Curr Oncol; 2023 Jan; 30(1):1077-1105. PubMed ID: 36661732
[TBL] [Abstract][Full Text] [Related]
29. Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders.
Angelini A; Castellucci P; Ceci F
PET Clin; 2019 Jan; 14(1):183-191. PubMed ID: 30420219
[TBL] [Abstract][Full Text] [Related]
30. PET/MRI in Gynecologic Malignancy.
Larson M; Lovrec P; Sadowski EA; Pirasteh A
Radiol Clin North Am; 2023 Jul; 61(4):713-723. PubMed ID: 37169433
[TBL] [Abstract][Full Text] [Related]
31. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
32. [Molecular imaging in oncological surgery: technical principles and importance].
Kotzerke J
Chirurg; 2014 Jun; 85(6):474-80. PubMed ID: 24805798
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
34. MR/PET: a new challenge in hybrid imaging.
Werner MK; Schmidt H; Schwenzer NF
AJR Am J Roentgenol; 2012 Aug; 199(2):272-7. PubMed ID: 22826387
[TBL] [Abstract][Full Text] [Related]
35. Potential applications of PET/MRI in non-oncologic conditions within the abdomen and pelvis.
Bartlett DJ; Takahashi H; Bach CR; Lunn B; Thorpe MP; Broski SM; Packard AT; Fletcher JG; Navin PJ
Abdom Radiol (NY); 2023 Dec; 48(12):3624-3633. PubMed ID: 37145312
[TBL] [Abstract][Full Text] [Related]
36. Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.
Shah HJ; Keraliya AR; Jagannathan JP; Tirumani SH; Lele VR; DiPiro PJ
Korean J Radiol; 2017; 18(1):54-70. PubMed ID: 28096718
[TBL] [Abstract][Full Text] [Related]
37. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
38. Interventional positron emission tomography/computed tomography: state-of-the-art.
Shyn PB
Tech Vasc Interv Radiol; 2013 Sep; 16(3):182-90. PubMed ID: 23993081
[TBL] [Abstract][Full Text] [Related]
39. Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis.
Wisenberg G; Thiessen JD; Pavlovsky W; Butler J; Wilk B; Prato FS
J Nucl Cardiol; 2020 Dec; 27(6):2118-2129. PubMed ID: 30603887
[TBL] [Abstract][Full Text] [Related]
40. PET/MR: a paradigm shift.
Gaertner FC; Fürst S; Schwaiger M
Cancer Imaging; 2013 Feb; 13(1):36-52. PubMed ID: 23446110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
